Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data At 2024 AHA Annual Meeting; New Zerlasiran Data Show Significant Time-Averaged Lp(a) Reductions With Effects Persisting 60 Weeks Following The First Dose
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data At 2024 AHA Annual Meeting; New Zerlasiran Data Show Significant Time-Averaged Lp(a) Reductions With Effects Persisting 60 Weeks Following The First Dose
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA (siRNA), in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L). These data were presented during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2024 in Chicago, Illinois, and simultaneously published in the Journal of the American Medical Association (JAMA).New zerlasiran data show significant time-averaged Lp(a) reductions with effects persisting 60 weeks following the first dose
新的zerlasiran数据显示，在首次给药后，Lp(a)的时间平均降低显著，效果持续60周。
Represents first study to report time-averaged Lp(a) results to further evaluate potential clinical benefits
这是第一项报告时间平均Lp(a)结果的研究，以进一步评估潜在的临床效益。
Data simultaneously published in the Journal of the American Medical Association
数据同时发表在《美国医疗协会杂志》中。
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a short interfering RNA (siRNA), in atherosclerotic cardiovascular disease (ASCVD) patients with high lipoprotein(a) [Lp(a)] levels (≥125 nmol/L). These data were presented during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2024 in Chicago, Illinois, and simultaneously published in the Journal of the American Medical Association (JAMA).
Silence therapeutics plc，纳斯达克：SLN（"Silence"或"公司"），是一家全球临床阶段的生物技术公司，致力于通过精确设计的药物通过沉默疾病来改变人们的生活，今天展示了其2期ALPACAR-360研究中zerlasiran的治疗结束数据，该研究针对高脂蛋白(a) [Lp(a)]水平（≥125 nmol/L）的动脉粥样硬化心血管疾病（ASCVD）患者。这些数据在美国心脏协会（AHA）2024年科学年会的最新科学会议上于伊利诺伊州芝加哥展示，并同时发表在《美国医疗协会杂志》（JAMA）上。
Results presented today showed that zerlasiran (300 mg every 16 weeks, 300 mg every 24 weeks or 450 mg every 24 weeks) produced greater than 80% mean time-averaged placebo-adjusted reductions from baseline in Lp(a) concentrations over 36 weeks. This is the first study to report time-averaged Lp(a) analyses, which more accurately evaluates the effects of treatment over time, including intervals between doses. Maximum Lp(a) reductions exceeded 90%. At the final visit, 60 weeks following initial drug administration, reductions in Lp(a) persisted and no safety concerns emerged with infrequent dosing.
今天展示的结果表明，zerlasiran（每16周300毫克， 每24周300毫克或每24周450毫克）在36周内使Lp(a)浓度的平均时间调整减少量超过80%。这是第一项报告时间平均Lp(a)分析的研究，更准确地评估了治疗在时间上的效果，包括给药间隔。最大Lp(a)降低超过90%。在最后一次访视中，首次用药后60周，Lp(a)的降低持续存在，并且没有出现任何安全隐患，给药频次不高。
